Company intelligence / Profile preview

Pharmuka Laboratoires

Ownership: Private
Development stage: Commercial

Overview

Pharmuka Laboratoires was a French pharmaceutical company best known for its pioneering work with low molecular weight heparins. Its most notable product, Fraxiparine® (nadroparin calcium), became widely used as an anticoagulant. The company's assets and operations were acquired by Sanofi in the 1980s, after which its brand ceased to exist independently.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

upstene

Commercial

Indications: Depression

Partnerships

Academic researchers (historical)

Beyond the preview

Go deeper on Pharmuka Laboratoires.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmuka Laboratoires.

Explore the full profile